List of Excipients in Branded Drug ANADROL-50

ANADROL-50 Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

ANADROL-50 is a 50 mg oral oxymetholone tablet used for selected anemias involving deficient red-cell production. Its commercial opportunity is driven less by active-ingredient exclusivity than by supply reliability, regulatory compliance, tablet performance, controlled-substance handling, and differentiated formulations. The legacy product has limited visible patent protection, leaving room for generic, authorized-generic, 505(b)(2), and hospital-supply strategies.[1][2]

What is ANADROL-50 and how is it regulated?

ANADROL-50 contains oxymetholone, an orally active anabolic androgenic steroid. The labeled indication is treatment of anemias caused by deficient red-cell production, including selected aplastic and hypoplastic anemias.[1]

Attribute	ANADROL-50
Active ingredient	Oxymetholone
Strength	50 mg per tablet
Dosage form	Immediate-release oral tablet
Original regulatory pathway	Full NDA product
Historical NDA	NDA 016885
Therapeutic area	Hematology and supportive care
Controlled-substance status	Schedule III anabolic steroid in the U.S.
Primary commercial constraints	Limited prescribing, safety monitoring, controlled-substance controls, supply continuity
Biosimilar exposure	None; oxymetholone is a small molecule

The label carries serious warnings involving hepatotoxicity, peliosis hepatis, liver tumors, lipid changes, edema, virilization, and endocrine effects. These risks constrain mass-market positioning and make formulation changes subject to close assessment of bioavailability and safety.[1]

What excipients are used in ANADROL-50?

The U.S. product labeling identifies a conventional tablet excipient system that includes lactose, microcrystalline cellulose, povidone, starch-based disintegrant materials, magnesium stearate, and silicon dioxide-type processing aids.[1][3] Exact inactive-ingredient listings should be taken from the current FDA label and DailyMed record used for the commercial lot or application under review.

The formulation profile is consistent with an immediate-release compressed tablet:

• Diluent for tablet mass and content uniformity
• Binder to support granulation and mechanical strength
• Disintegrant to promote breakup after administration
• Glidant to improve powder flow
• Lubricant to reduce tooling adhesion
• Lactose or another filler to support tablet compression

The principal excipient issue is not chemical novelty. It is whether a reformulated product can improve manufacturability, supply resilience, patient acceptability, or regulatory differentiation without changing oxymetholone exposure.

What excipient strategy is appropriate for oxymetholone tablets?

The strongest near-term strategy is a robust, conventional immediate-release formulation with improved process capability and reduced dependence on a narrow supplier set. A new excipient platform should solve a defined commercial problem rather than add complexity to an established 50 mg tablet.

Strategy 1: Improve manufacturing robustness

A direct-compression or dry-granulation platform can reduce dependence on water-sensitive processing and shorten manufacturing time. Suitable excipient classes include:

• Spray-dried lactose or co-processed lactose-cellulose systems
• Microcrystalline cellulose for compactibility
• Crospovidone or sodium starch glycolate for rapid disintegration
• Low-moisture binders for improved stability
• Colloidal silicon dioxide for flow control
• Sodium stearyl fumarate or magnesium stearate for lubrication

The formulation must control blend uniformity because oxymetholone is present at a relatively high 50 mg dose but still requires consistent distribution throughout the blend. Excessive lubricant can slow dissolution. High compression force can produce a tablet that meets hardness specifications but fails disintegration or dissolution targets.

Strategy 2: Reduce excipient-related tolerability barriers

A lactose-free or low-lactose product could address patients with lactose intolerance or institutions seeking a simplified excipient profile. This is a modest differentiation opportunity, not a basis for a premium price by itself.

Potential lactose replacements include:

• Mannitol
• Dibasic calcium phosphate
• Microcrystalline cellulose
• Pregelatinized starch
• Co-processed filler-binder systems

Calcium phosphate can improve tablet hardness but may create different disintegration and dissolution behavior. Mannitol can improve mouthfeel but may increase tablet size or cost. A switch from lactose to another filler also requires review of hygroscopicity, compression behavior, and supplier qualification.

Strategy 3: Stabilize supply and reduce nitrosamine or impurity risk

Oxymetholone products require an impurity-control strategy covering active ingredient, excipients, packaging, and manufacturing conditions. A supplier-diversification program should qualify at least two sources for each critical excipient where feasible.

The formulation team should evaluate:

• Peroxide levels in excipients
• Residual moisture
• Trace metals
• Oxidative degradation
• Packaging permeability
• Extractables and leachables
• Compatibility with desiccants
• Stability under accelerated and long-term conditions

A high-barrier blister or bottle system can protect against moisture and oxygen. The commercial value is greatest where supply interruptions have resulted from manufacturing deviations, packaging failures, or limited active-ingredient availability.

Strategy 4: Improve swallowing and administration

ANADROL-50 is a relatively large-strength tablet. A smaller tablet could improve administration if higher drug loading or a more efficient excipient system is achieved. A scored tablet may support dose flexibility, but score-line performance must be validated for uniformity of divided portions.

Potential dosage-form extensions include:

• Smaller immediate-release tablet
• Dispersible tablet
• Oral suspension
• Orally disintegrating tablet
• Unit-dose hospital packaging

Each option changes the regulatory and commercial risk profile. A liquid formulation introduces sedimentation, wetting, preservative, microbial, and dose-measurement issues. An orally disintegrating tablet may improve administration for selected patients but requires taste-masking and rapid-disintegration work. Oxymetholone’s use in a medically supervised, relatively narrow population limits the likely return from a consumer-oriented ODT program.

What formulation patents could protect an ANADROL-50 reformulation?

A conventional composition containing oxymetholone, lactose, cellulose, povidone, a disintegrant, and magnesium stearate is unlikely to provide strong patent differentiation unless the formulation produces an unexpected technical effect.

Potentially protectable subject matter includes:

Candidate	Possible claim focus	Commercial value
Low-moisture tablet	Defined water activity and stability profile	Moderate
Rapid-disintegrating tablet	Disintegration and dissolution thresholds	Moderate
Low-impurity formulation	Controlled degradation products over shelf life	Moderate to high if technically demonstrated
Lactose-free formulation	Composition and patient-use characteristics	Low to moderate
Smaller high-load tablet	Drug loading, hardness, friability, dissolution	Moderate
Modified-release tablet	Release profile and dosing schedule	High regulatory risk
Oral suspension	Particle-size control, sedimentation, preservative system	Niche
Abuse-deterrent formulation	Resistance to crushing, extraction, or manipulation	Potentially high, but likely limited market

Patent strength would depend on unexpected results, narrow and reproducible formulation ranges, and evidence that the formulation solves a real technical problem. Broad claims covering ordinary tablet excipients would face substantial obviousness risk.

A formulation patent could be filed as a composition-of-matter or pharmaceutical-composition application. Method-of-use claims could focus on administration in a defined anemia population, but the existing indication and known pharmacology would make broad use claims difficult to defend.

When does ANADROL-50 lose exclusivity?

ANADROL-50’s core active-ingredient exclusivity is long expired. Oxymetholone was introduced decades ago, and any original composition, formulation, or regulatory exclusivity periods have ended.[1][2]

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Original formulation patent term	Expired or no longer commercially material
Orphan-drug exclusivity	No current seven-year exclusivity identified for the legacy product
Pediatric exclusivity	No current six-month extension identified
New formulation exclusivity	Available only if a new qualifying product is approved
Generic entry	Legally possible subject to FDA approval and controlled-substance requirements

The principal commercial barrier is therefore execution, not basic patent exclusivity. A sponsor seeking protection would need to create a new FDA-recognized formulation, delivery system, indication, or clinical benefit.

What is the Orange Book status of ANADROL-50?

The Orange Book is the relevant FDA publication for approved drug products, therapeutic equivalence evaluations, and listed patents where applicable.[2] Legacy products can have changing marketing status, discontinued presentations, and limited current listing visibility. The commercial assessment should distinguish among:

1. The original NDA record.
2. Current marketed status.
3. Therapeutically equivalent products.
4. Any listed patents or exclusivity codes.
5. Withdrawn or discontinued presentations.

For a legacy oxymetholone tablet, the practical conclusion is that Orange Book patent protection is unlikely to block a properly supported generic application. A sponsor must still review the current edition and FDA listing status before filing because product-level status can change.

Are Paragraph IV challenges relevant to ANADROL-50?

Paragraph IV litigation risk is likely limited for the legacy product because the central patent term has expired. If no unexpired patents are listed for the reference product, an ANDA applicant would not need to make a Paragraph IV certification against a current Orange Book patent.

Paragraph IV exposure could arise if a new sponsor obtains listing for:

• A novel controlled-release formulation
• A new dosage form
• A newly approved indication
• A device or administration system
• A qualifying method-of-use claim

A future ANDA sponsor should examine whether any listed method-of-use patent is relevant to the proposed label. Carve-outs may be possible when the patented use can be omitted without undermining the remaining approved labeling.

What generic entry risks exist for ANADROL-50?

Generic entry risk is structurally high because the active ingredient is old and the product is an immediate-release tablet. The main obstacles are operational.

Regulatory risks

An ANDA sponsor would need to demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements. The formulation should match the reference product in strength, dosage form, route of administration, and relevant quality attributes.[4]

Key development risks include:

• Dissolution differences caused by lubricant level or compression force
• Excipients that alter wetting or disintegration
• Batch-to-batch content-uniformity variation
• Stability failures caused by moisture or oxidation
• Difficulty obtaining a reliable reference product
• Controlled-substance registration and quota requirements

Manufacturing and supply risks

Oxymetholone is a specialized active ingredient with a narrower market than common generic drugs. A low-volume product can become uneconomic if the active-ingredient supplier has a manufacturing interruption or if quality-control costs rise.

A resilient commercial program should include:

• Dual-source active ingredient where feasible
• Qualified excipient alternatives
• Controlled-substance inventory controls
• High-barrier packaging
• Small, flexible batch capability
• Contract manufacturing with DEA-compliant infrastructure
• Forecasting based on institutional and specialty-pharmacy demand

Which companies are challenging ANADROL-50?

The competitive field is likely to consist of generic manufacturers, specialty suppliers, and contract manufacturers rather than branded innovators pursuing major patent disputes. Public information may not consistently identify all current applicants, private-label distributors, or discontinued manufacturers.

The most relevant competitor groups are:

Competitor group	Advantage	Limitation
Established generic companies	Regulatory infrastructure and purchasing access	Limited incentive in a small market
Specialty generic manufacturers	Willingness to serve low-volume products	Smaller distribution footprint
Authorized or private-label suppliers	Existing commercial channels	Dependence on third-party manufacturing
Hospital-focused suppliers	Institutional relationships	Narrower outpatient reach
Compounding pharmacies	Customization and shortage response	Cannot substitute broadly for FDA-approved manufacturing

No biosimilar competition exists because oxymetholone is a chemically synthesized small molecule, not a biologic.

What commercial opportunities exist for an ANADROL-50 reformulation?

The largest opportunity is a reliable, FDA-approved generic or authorized-generic product with stable supply and competitive institutional pricing. A reformulation can add value where it reduces manufacturing failure, improves shelf life, or addresses a clear administration problem.

Opportunity ranking

Opportunity	Market potential	Regulatory burden	Patent potential
Standard generic 50 mg tablet	Moderate	Moderate	Low
Lactose-free tablet	Low to moderate	Moderate	Low
Smaller high-load tablet	Moderate	Moderate	Moderate
Moisture-protected presentation	Moderate	Moderate	Moderate
Hospital unit-dose packaging	Moderate	Low to moderate	Low
Oral suspension	Low to moderate	High	Moderate
ODT formulation	Low to moderate	High	Moderate
Modified-release product	Uncertain	High	High
Abuse-deterrent product	Low	Very high	High

A differentiated product could target hematology clinics, hospital pharmacies, specialty distributors, and shortage-sensitive buyers. The product should not be positioned as a broad anabolic-steroid opportunity because the FDA indication, safety profile, Schedule III status, and narrow clinical use limit that market.

Revenue exposure

Revenue is likely concentrated among a relatively small number of prescribers and institutional purchasers. Commercial performance will depend on:

• Product availability
• Wholesaler stocking
• Payer coverage
• Generic price competition
• Clinical demand in aplastic and hypoplastic anemia
• Regulatory supply continuity
• Controlled-substance distribution capability

A premium formulation is unlikely to support substantial pricing unless it provides measurable clinical or operational value. The strongest value proposition is dependable supply with a clean label, validated stability, and low switching friction.

What patent litigation and settlement issues affect ANADROL-50?

No major active patent-litigation pattern is associated with the legacy oxymetholone tablet comparable to litigation involving newer blockbuster drugs. The likely legal issues are product-specific:

• ANDA certification strategy
• Reference-listed-drug status
• Patent listing for a later reformulation
• Trade dress and trademark rights
• Controlled-substance distribution compliance
• Contract manufacturing and supply agreements
• Antitrust risk in any generic settlement

A settlement could become relevant only if a new formulation patent or method-of-use patent creates an ANDA delay dispute. For the legacy product, settlement economics are less compelling because the underlying active ingredient has no meaningful remaining composition-of-matter exclusivity.

How strong is the ANADROL-50 patent estate?

The legacy patent estate is weak from a blocking perspective. The active ingredient is old, the dosage form is conventional, and any new protection would need to arise from a genuinely differentiated formulation or use.

Strength assessment

• Core molecule: expired protection
• Standard immediate-release tablet: low patent strength
• Excipient substitution alone: low patent strength
• Stability-driven formulation: moderate if supported by unexpected data
• Modified release: potentially stronger, but higher development risk
• New indication: uncertain and clinically demanding
• Manufacturing process: moderate if the process improves purity, yield, or impurity control

Geographic coverage outside the United States depends on country-specific patent histories and regulatory approvals. Because the product is old, most original international patent terms are also expected to have expired. New formulation filings would require separate national-phase and enforcement analysis.

What is the recommended excipient and commercial plan?

A practical development plan is:

1. Use an immediate-release tablet as the base product.
2. Develop a lactose-free or reduced-lactose option only if a commercial customer supports it.
3. Prioritize low-moisture, low-peroxide excipient grades.
4. Validate rapid and complete dissolution across the proposed manufacturing range.
5. Use high-barrier packaging and confirm long-term stability.
6. Qualify alternate excipient and active-ingredient suppliers.
7. File an ANDA for the conventional product where reference-product access is adequate.
8. Consider a 505(b)(2) pathway only for a clinically meaningful dosage-form or administration improvement.[5]
9. Avoid modified release unless a clear dosing or adherence benefit justifies clinical and regulatory cost.
10. Build distribution around specialty pharmacy, hematology clinics, and hospital systems.

Key Takeaways

• ANADROL-50 is a 50 mg oxymetholone immediate-release tablet for selected anemias.
• Core molecule and legacy product exclusivity have expired.
• Biosimilar risk is irrelevant; generic competition is the relevant threat.
• The most attractive excipient strategy is a robust, conventional tablet with improved stability and supply resilience.
• Lactose-free, smaller-tablet, moisture-protected, and hospital unit-dose products offer practical differentiation.
• ODT, liquid, modified-release, and abuse-deterrent products carry higher regulatory and commercial risk.
• Patent value will depend on unexpected technical effects, not routine excipient substitution.
• The strongest commercial opportunity is dependable FDA-approved supply rather than premium pricing based solely on formulation novelty.
• Controlled-substance compliance and active-ingredient sourcing may be more important than patent barriers.

FAQs About ANADROL-50 Excipient and Commercial Strategy

Can oxymetholone be reformulated without new clinical trials?

A conventional equivalent tablet may qualify for an ANDA if it meets FDA pharmaceutical-equivalence and bioequivalence requirements. A materially different dosage form or release profile may require a 505(b)(2) application and additional clinical or pharmacokinetic evidence.[4][5]

Is a lactose-free ANADROL-50 tablet commercially attractive?

It can address excipient sensitivity and institutional formulary preferences, but the opportunity is niche. Lactose removal alone is unlikely to support durable patent protection or substantial price premium.

Would an oxymetholone oral suspension have market value?

A suspension could support patients unable to swallow tablets, but it creates development issues involving dose uniformity, sedimentation, microbial control, preservative effectiveness, packaging, and stability. Its value depends on documented demand from specialty-care settings.

Can a new ANADROL-50 formulation receive three years of FDA exclusivity?

A new application containing new clinical investigations essential to approval may qualify for three-year exclusivity under applicable FDA rules. A routine excipient change without essential new clinical data generally would not create the same exclusivity.[6]

Are compounding pharmacies a major competitor to generic ANADROL-50?

They may provide limited customized access during shortages or for specific patients, but compounded products do not generally provide the same substitution, quality-system, labeling, or distribution position as an FDA-approved commercial tablet.

References

1. U.S. Food and Drug Administration. (n.d.). ANADROL-50 (oxymetholone) tablet prescribing information. FDA/DailyMed labeling record.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA, Center for Drug Evaluation and Research.

3. National Library of Medicine. (n.d.). DailyMed: ANADROL-50 oxymetholone tablet. DailyMed.

4. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA, Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA, Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2024). New drug product exclusivity. FDA, Center for Drug Evaluation and Research.